Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Attention Danaher Corporation ("Danaher") (NYSE: DHR) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased between April 21, 2022 and April 24, 2023. If you suffered a loss on your investment in Danaher, contact us about potential recovery by using the link below.

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Danaher Investors of a Lead Plaintiff Deadline of September 15, 2023

NEW YORK , Aug. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased Danaher securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Danaher Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DHR

NEW YORK , Aug. 11, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Danaher Corporation (NYSE: DHR). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/danaher-class-action-loss-submission-form/?id=43314&from=4 The lawsuit seeks to recover losses for shareholders who purchased Danaher between April 21, 2022 and April 24, 2023.

DHR SHAREHOLDER ALERT: Jakubowitz Law Reminds Danaher Shareholders of a Lead Plaintiff Deadline of September 15, 2023

Bath and Body Works

Jacobs Solutions Inc

It's not often that you read about activist investor Dan Loeb praising the chief executive officer (CEO) of a company in which Third Point Management holds a stake, but that's precisely what happened in the hedge fund's July 31 investor letter, which laid out its thoughts on some of Dan Loeb's stock picks. Third Point first took a stake in Shell (NYSE: SHEL ) in 2021, doling out $750 million in the Dutch oil giant.

A Billionaire's Bet: 3 Stocks Dan Loeb Thinks You Should Own

NEW YORK , Aug. 4, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased Danaher securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Danaher Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DHR

Charles River Laboratories

Medtronic

As a prolific cog in the economic machine, the healthcare industry has been a roller coaster ride over the past few years. With the global pandemic, economic slowdown and industry-wide disruptions in play, healthcare stocks took a major hit but are now demonstrating signs of recovery.

Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points

Bristol-Myers

Johnson & Johnson

ProShares S&P 500 Dividend Aristocrats ETF

PepsiCo

Procter & Gamble

Invesco S&P 500 High Beta ETF

Thermo Fisher Scientific

UnitedHealth Group

iShares Edge MSCI Min Vol USA ETF

Health Care Select Sector SPDR Fund

High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO's research shows that low-volatility investing can significantly improve long-term performance, particularly in market environments with increased retail investor participation. Low-risk ETFs, such as healthcare names and dividend aristocrats, offer exposure to fundamentally strong factors and tend to perform well during periods of stagflation, high inflation, and decent economic growth.

Time To Go Defensive With These ETFs

LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

NEW YORK , July 27, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Danaher Corporation (NYSE: DHR) between April 21, 2022 and April 24, 2023, both dates inclusive (the "Class Period"), of the important September 15, 2023 lead plaintiff deadline. SO WHAT: If you purchased Danaher securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING LAW FIRM, Encourages Danaher Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DHR

Intuitive Surgical

Eli Lilly

McKesson

Teladoc

Healthcare continues to be a major industry and economic driver around the world. According to the American Medical Association, spending on healthcare in the U.S. totals more than $4 trillion each year, which works out to nearly $13,000 per person.

7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes

Alphabet

TROY, Mich. , July 26, 2023 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Danaher Corp. (NYSE: DHR) as its "Stock to Study" and Alphabet Inc. (NASDAQ: GOOG) – the parent company of Google – as its "Undervalued Stock" in the October 2023 issue for investors' informational and educational use.

BetterInvesting™ Magazine Update on Danaher Corp. and Alphabet Inc.

With a daily gain of 3.15% and Earnings Per Share (EPS) (EPS) of $8.52, Danaher Corp ( DHR , Financial) presents a compelling case for value investors. The question we aim to answer is: Is Danaher (DHR) modestly undervalued?

Is Danaher (DHR) Modestly Undervalued? An In-depth Analysis

LOS ANGELES, CA / ACCESSWIRE / July 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Danaher Corporation ("Danaher" or "the Company") (NYSE:DHR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 21, 2022 and April 24, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before September 15, 2023.

INVESTOR DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Danaher Corporation with Losses of $100,000 to Contact the Firm

Mastercard

Grupo Aeroportuario del Pacifico

Roper Technologies

Starbucks

Taiwan Semiconductor Manufacturing

Texas Instruments

After a dismal 2022, investors have returned to the top growth stocks to buy with great enthusiasm. We shouldn't forget the lessons from 2022, however.

7 Growth Stocks You Better Be Buying on Each and Every Dip

NEW YORK , July 25, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR), and certain officers.  The class action, filed in the United States District Court for the District of Columbia, and docketed under 23-cv-02055, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Danaher securities between April 21, 2022, and April 24, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHODER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Danaher Corporation of Class Action Lawsuit and Upcoming Deadline - DHR

Danaher's (DHR) Q2 earnings and revenues beat estimates. However, a decline in the sale of COVID-related products weigh on the top line.

Danaher (DHR) Q2 Earnings Beat, Sales Decline 7.7% Y/Y

ANAHEIM, Calif. , July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer, addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion.

Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

ANAHEIM, Calif. , July 25, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, received FDA clearance for its new DxC 500 AU Chemistry Analyzer, an automated chemistry analyzer, expanding the company's clinical chemistry offering and demonstrating ongoing commitment to product innovation in the in vitro diagnostic industry.

Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance

Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Danaher (DHR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Danaher Corporation (NYSE:DHR ) Q2 2023 Earnings Conference Call July 25, 2023 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President and CEO Matt McGrew - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - TD Cowen Puneet Souda - Leerink Partners Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator My name is Ashley, and I'll be your facilitator this morning. At this time, I would like to welcome everyone to the Danaher Corporation Second Quarter 2023 Earnings Conference Call.

Danaher Corporation (DHR) Q2 2023 Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $DHR #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Danaher Corporation ("Danaher" or the "Company") (NYSE: DHR) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Danaher sec.

Calling All Danaher Corporation (DHR) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!

Danaher Corp on Tuesday cut its annual sales growth forecast for a second straight quarter, signaling that funding crunch in the drug development market was weighing on its biotechnology business.

Danaher cuts forecast for annual sales growth as biotech clients face funding crunch

WASHINGTON , July 25, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2023.  Net earnings refer to net earnings attributable to common shareholders.

Danaher Reports Second Quarter 2023 Results

Danaher is an industry-leading serial acquirer with an iconic business system. After a boom in Danaher's sales during the pandemic, demand is now slowing as customers are facing inventory build-up and liquidity challenges. Beyond the current headwinds, Danaher's market position, balance sheet and cash flow generation remain strong and will position the company for secular growth over the long term.

Danaher: A Compounding Icon At A Fair Price

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Danaher Corporation (“Danaher” or the “Company”) (NYSE: DHR) in the United States District Court for the District of Columbia on behalf of all persons and entities who purchased or otherwise acquired Danaher securities between April 21, 2022 and April 24, 2023, both dates inclusive (the “Class Period”). Investors have until.

DANAHER ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Danaher Corporation and Encourages Investors to Contact the Firm

News for Danaher Stock (DHR)